DC Chemicals · Product datasheet

Foxy-5(Wnt5a peptide mimetic) — Datasheet

CAT. NO. DC23893

Product page and current package options

ParameterValue
Chemical Name(2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid
CAS No.881188-51-8
SynonymsFoxy 5, Wnt5a peptide mimetic,FOXY-5,FOXY5
FormulaC26H42N6O12S2
M.Wt694.77
SMILES[H]N([C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)C(=O)[C@H](CCSC)NC=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Foxy-5 is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 is a WNT5A agonist and effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2].

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1]. Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer[2].

Target

WNT5A[1]

References & source

[1]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.

[2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation